Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.

Nephron - 1 Jan 2015

Tøndel Camilla, Kanai Takahiro, Larsen Kristin Kampevold, Ito Shuichi, Politei Juan Manuel, Warnock David G, Svarstad Einar

Abstract excerpt

UNLABELLED: In Fabry disease, globotriaocylceramid (GL3) starts to accumulate in kidney cells in utero, and continues to accumulate throughout childhood and adulthood with progressive tissue damage, which may lead to renal failure. MATERIAL AND METHODS: Eight children with classical Fabry disease, median age 12 (range 4-16 years) had a renal biopsy performed before the initiation of enzyme replacement therapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albuminuria
Share to alpha-Galactosidase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Replacement Therapy

Share to Fabry Disease

Share to Kidney Diseases

Share to Microscopy, Electron, Transmission

Share to Podocytes

Share to Trihexosylceramides

Source

Identifiers

PMID: 25531941
DOI: 10.1159/000369309

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.PMID 25531941Read ↗

Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.Semantic proximity Read ↗

Early renal failure in childhood in a male with Fabry disease.Semantic proximity Read ↗

Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy.Semantic proximity Read ↗

Fabry Disease Nephropathy: Histological Changes With Nonclassical Mutations and Genetic Variants of Unknown Significance.Semantic proximity Read ↗

Diagnosing Fabry nephropathy: the challenge of multiple kidney disease.Semantic proximity Read ↗

Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease.Semantic proximity Read ↗

Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid systemSemantic proximity Read ↗

Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid systemSemantic proximity Read ↗

CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model.Semantic proximity Read ↗

[A boy with Fabry disease with the onset at the age of four].Semantic proximity Read ↗

Kidney transplantation from a mother with unrecognized Fabry disease to her son with low α-galactosidase A activity: A 14-year follow-up without enzyme replacement therapy.Semantic proximity Read ↗

Urine-derived cells: a promising diagnostic tool in Fabry disease patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.